Revivent TC Less Invasive Ventricular Enhancement Therapy CE Mark Extended to 2024

Revivent TC Less Invasive Ventricular Enhancement Therapy CE Mark Extended to 2024

BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, has announced the extension of the system's CE Mark.Recently covered on our pages with news of promising one year study data, Revivent is a less invasive ventricular...

Latest News

First Scoring Guidelines Validated for WatchPAT™ Sleep Apnea Diagnostic

Respiratory Sleep Disorder specialist, Itamar Medical Ltd. has announced publication of results of...

read the full article >

Promise for Emboliner™ Embolic Protection Catheter as Safepass 2 Study Completes Enrollment

Emboline™, Inc., developer of total embolic protection technology for transcatheter aortic valve...

read the full article >

Cardiology

Approvals / Clearance

Clinical Studies / Trials